Table 1.
Characteristics of screened compounds
| Drug name | Screen concentration | Category* | Clinical use | Known target(s) | Reference |
|---|---|---|---|---|---|
| Methotrexate |
60 nM |
Antimetabolites/ immunosuppressants |
Antineoplastic |
DHFR |
[20] |
| Antirheumatic | |||||
| Dermatologic agent | |||||
| Aminopterin |
20 nM |
Antimetabolites (discontinued) |
Dermatologic agent (phase I) |
DHFR, FPGS(?) |
[21] |
| Antineoplastic agent (phase II) | |||||
| Orlistat |
20 μM |
Antiobesity preparations, excluding diet products |
Anti-obesity agent |
LPL |
[22] |
| PNLIP |
[23] |
||||
| FASN | |||||
| Bleomycin |
1 μM |
Cytotoxic antibiotics and related substances |
Antineoplastic agent |
DNA |
[24] |
| LIG1 | |||||
| LIG3 | |||||
| Cisplatin |
2 μM |
Other antineoplastic agents |
Antineoplastic agent |
DNA |
[25] |
| Mitomycin C |
80 nM |
Cytotoxic antibiotics and related substances |
Antineoplastic agent |
DNA |
[26] |
| 17_DMAG | 70 nM | Experimental Hsp90 inhibitor | Antineoplastic agent (phases I and II) | Hsp90 |
[27] |
| HSP90AA1 | |||||
| HSP90AA2 | |||||
| HSP90B1 | |||||
| HSP90AB1 |